Pembrolizumab (Keytruda) is a targeted therapy used to treat a wide range of tumors. Unfortunately, it can have a negative impact on a fetus.
Mechanism: humanized monoclonal antibody
Target: PD-1/PD-L1
Blocking of PD-1/PD-L1 cause T cells to target tumor cells. Blockade may also cause T-cells to attack normal host cells (autoimmune reaction).
Adverse effects of pembrolizumab on a fetus:
(1) increased risk of abortion or stillbirth
(2) altered immune function with potential for immune-mediated disorders
Congenital malformations have not been described.
A woman who is in her reproductive years should use an effective method of contraception.
